Konstantin Konstantinov

Chief Technology Officer
Codiak BioSciences

During his 30-year career, Dr. Konstantinov has been at the forefront of development and implementation of advanced biomanufacturing technologies. He has been involved in the commercialization of different biotherapeutic modalities, including monoclonal antibodies, blood factors, enzymes, gene therapy constructs, and exosomes produced by mammalian cells. He has published 60 peer-reviewed papers, and has more than 15 patents and patent applications.  Over the last decade, he has pioneered the development of the integrated continuous biomanufacturing, which is becoming a trend for the biomanufacturing industry worldwide.

Konstantin is the Chief Technology Officer at Codiak BioSciences in Cambridge, MA, where he is responsible for the development, scale up, manufacturing and characterization of the novel exosome-based biotherapeutics.  He joined Codiak when the company was founded, and helped build the organization from the ground up.

Before Codiak, he served as a Vice President of late-stage process and technology development at Genzyme/Sanofi. Prior to that, Konstantin worked for 14 years for Bayer in Berkeley, CA.

Dr. Konstantinov received his Ph.D. in Biochemical Engineering from Osaka University, Japan, which was followed by a post-doctoral assignment at DuPont and the University of Delaware.  Konstantin is the recipient of several prestigious awards, including the 1992 Award of the Japanese Society of Fermentation Technology, the 2004 ACS-BIOT Industrial Award (for Bayer Corp), the 2016 Cell Culture Engineering Award, the 2017 Integrated Continuous Biomanufacturing Award, and the 2020 ACS/AIChE Professor Daniel Wang Award for Excellence in Biochemical Engineering.